You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

933 Results
Document
Document
Document
Document
Document
Document
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    olaparib - For the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
Dec 2024
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Apr 2024
Drug
Other Name(s): Nubeqa®
Aug 2025

Pages